Hypertensive nephropathy primary prevention

Hypertensive nephropathy Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Differentiating Hypertensive Nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Abdominal X Ray
CT
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypertensive nephropathy primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hypertensive nephropathy primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypertensive nephropathy primary prevention
CDC on Hypertensive nephropathy primary prevention
Hypertensive nephropathy primary prevention in the news
Blogs on Hypertensive nephropathy primary prevention
Directions to Hospitals Treating Hypertensive nephropathy
Risk calculators and risk factors for Hypertensive nephropathy primary prevention

• Renin–angiotensin–aldosterone (RAAS) blockers such as ACEI or ARB play a significant role in preventing progression to ESRD by controlling blood pressure in hypertensive patients.
• According to 2017 guidelines, the goal of BP is < 130/80 mmHg for patients with hypertension and CKD regardless of proteinuria.